Nomura全球上市基礎設施主動型ETF BILD 深 滬
等待開盤 06-25 09:30:00 美东时间
29.5249
+0.198
+0.68%
華盛通- 最 高29.5249
- 今 開29.3267
- 成交量 52股
- 最 低 29.5249
- 昨 收 29.3267
- 總市值 738.12万
- 52周最高 30.8272
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 25.124
- 委 比 0.00%
- 總股本 25.00万
- 歷史最高 30.8272
- 量 比 0
- 振 幅 0.00%
- 歷史最低 20.8967
- 每 手 1
- 風險率 1.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BuildDirect.com Technologies GAAP EPS of -$0.04, revenue of $14.6M
BuildDirect.com Technologies press release (BILD:CA): Q1 GAAP EPS of -$0.04. Revenue of $14.6M. More on BuildDirect.com Technologies BuildDirect.com Technologies Inc. (BILD:CA) Q1 2026 Earnings Call T...
05-30 02:50
United Therapeutics Says New England Journal Of Medicine Publishes Full Results Of TETON-1 Study And Combined Analyses Of TETON-1, TETON-2 Studies, Evaluating Use Of Nebulized Tyvaso For Treatment Of IPF
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and
05-19 04:17
BuildDirect.com Technologies reports Q4 results
BuildDirect.com Technologies press release (BILD:CA): Q4 Revenue of $66.2M. Gross margin of 40.4% in FY 2025, an increase of 170 bps from 38.7% in FY 2024. Gross profit of $26.7 million, an increase o...
04-15 03:55
United Therapeutics' TETON-1 Study Of Nebulized Tyvaso For Idiopathic Pulmonary Fibrosis Met Its Primary Efficacy Endpoint, Demonstrating Superiority Over Placebo For The Change In Absolute Forced Vital Capacity From Baseline To Week 52
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its
03-30 19:10
美股盘后 | UL Solutions Inc. Class A涨14.63%，F5网络涨10.20%
UL Solutions Inc. Class A涨14.63%；F5网络涨10.20%；Nextpower Inc. Class A涨8.57%
01-28 07:11
美股盘后 | Venture Global涨7.18%，Karman Holdings Inc.涨6.55%
Venture Global涨7.18%；Karman Holdings Inc.涨6.55%；Moderna涨3.79%
01-22 07:11
Shanghai Henlius Biotech Inc. Receives FDA Approval for Two Products, BILDYOS® and BILPREVDA®, for Eight Indications Including Osteoporosis
Shanghai Henlius Biotech Inc. has announced that the United States Food and Drug Administration (FDA) has approved two of its products, HLX14 (denosumab-NXXP), under the trade names BILDYOS® and BILPR...
2025-09-01 19:16
